- 1 in 8 adults are forecast to suffer from diabetes by 2024, with over 1 in 10 deaths in 2021 a direct result of the disease
- As many as 40% of Covid-19 related fatalities in the US also suffered from diabetes at the time of their passing
- Nemaura Medical is a medical technology company focused on developing non-invasive wearable diagnostic devices
- In addition to sugarBEAT, its flagship device, the company also recently announced the launch of MiBoKo, a combined application and non-invasive glucose sensor designed to help users track their metabolic scores
By 2024, the International Diabetes Federation (“IDF”) predicts that the number of people with diabetes is expected to rise to 1 in 8 adults. Nearly 7 million adults have died worldwide in 2021 so far due to diabetes or its related complications – astoundingly, accounting for over 1 in 10 global deaths from any cause. While enormous, that figure does not consider the lives lost to the novel coronavirus, which has shown to be particularly deadly for people with diabetes. A study found that having Type 1 or Type 2 diabetes tripled the risk of severe illness or death from COVID-19 (https://ibn.fm/laj37).
“As many as 40% of the people that have died in the US from COVID-19 had diabetes,” said Dr. Robert Gabbay, chief scientific and medical officer for the…
NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
